I had also noted this a few days ago, and while it’s yet more validation of Anktiva having medical/scientific value, I just couldn’t get up the enthusiasm to post about it here, because as we have already discussed among ourselves, it’s about monetizing the science for our purposes as investors: ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - ImmunityBio
While today's news is certainly a step in the direction, here’s the ChatGPT summary of the disease, which indicates that it does not appear to be as “serious” as others (then again, it’s easy to describe it as such is easy if you’re not afflicted with it):
- Waldenstrom macroglobulinemia (WM) has a generally good prognosis, with many patients living for 10 years or more after diagnosis. The 5-year survival rate is around 78%, and the 10-year survival rate is about 64%, though these numbers can vary based on individual factors and treatment advancements. While not curable, WM is often manageable with various treatment options, and some patients may live for 14 to 16 years or more after diagnosis, particularly with newer treatments.
Two complete responses is further validation that Anktiva is not merely some snake oil, but unless and until we see the company’s management to deliver news other than what a great science project this appears to be, I will remain [marginally, but involuntarily] patient….MAF |
